{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:07:50Z","timestamp":1792670870834,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.vaccine.2022.01.050","type":"journal-article","created":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T12:34:05Z","timestamp":1644237245000},"page":"1421-1438","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Safety and immunogenicity of an investigational quadrivalent meningococcal tetanus toxoid conjugate vaccine (MenACYW-TT) co-administered with routine pediatric vaccines in infants and toddlers: A Phase II study"],"prefix":"10.1016","volume":"40","author":[{"given":"Matthew J.","family":"Cornish","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Hedrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvin A.","family":"Gabrielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony D.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Miriam Pina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Rehm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Neveu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Da Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Jordanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandeep S.","family":"Dhingra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.01.050_b0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-61779-346-2_1","article-title":"Neisseria meningitidis: biology, microbiology, and epidemiology","volume":"799","author":"Rouphael","year":"2012","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.vaccine.2022.01.050_b0010","unstructured":"World Health Organization (WHO). Meningococcal meningitis \u2013 Fact sheet. Geneva, Switzerland: World Health Organization (WHO); 2018."},{"issue":"4","key":"10.1016\/j.vaccine.2022.01.050_b0015","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s40121-018-0213-2","article-title":"Systematic review of invasive meningococcal disease","volume":"7","author":"Olbrich","year":"2018","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.vaccine.2022.01.050_b0020","series-title":"Enhanced meningococcal disease surveillance report, 2018","author":"United States Centers for Disease Control and Prevention","year":"2018"},{"issue":"2","key":"10.1016\/j.vaccine.2022.01.050_b0025","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jadohealth.2016.04.012","article-title":"The global evolution of meningococcal epidemiology following the introduction of meningococcal vaccines","volume":"59","author":"Pelton","year":"2016","journal-title":"J Adolesc Health"},{"issue":"18","key":"10.1016\/j.vaccine.2022.01.050_b0030","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1016\/j.vaccine.2011.02.058","article-title":"The Global Meningococcal Initiative: recommendations for reducing the global burden of meningococcal disease","volume":"29","author":"Harrison","year":"2011","journal-title":"Vaccine"},{"issue":"27","key":"10.1016\/j.vaccine.2022.01.050_b0035","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1016\/j.vaccine.2013.04.036","article-title":"Emergence of serogroup X meningococcal disease in Africa: need for a vaccine","volume":"31","author":"Xie","year":"2013","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2022.01.050_b0040","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1080\/21645515.2018.1532248","article-title":"Recent changes in the epidemiology of Neisseria meningitidis serogroup W across the world, current vaccination policy choices and possible future strategies","volume":"15","author":"Booy","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2022.01.050_b0045","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines6010012","article-title":"Meningococcal vaccines: current status and emerging strategies","volume":"6","author":"McCarthy","year":"2018","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2022.01.050_b0050","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/INF.0b013e3180cc2c25","article-title":"Reconsideration of the use of meningococcal polysaccharide vaccine","volume":"26","author":"Granoff","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2022.01.050_b0055","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1182\/blood-2004-01-0346","article-title":"Human blood IgM \u201cmemory\u201d B cells are circulating splenic marginal zone B cells harboring a prediversified immunoglobulin repertoire","volume":"104","author":"Weller","year":"2004","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.vaccine.2022.01.050_b0060","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.it.2004.11.004","article-title":"Vaccination against encapsulated bacteria in humans: paradoxes","volume":"26","author":"Weller","year":"2005","journal-title":"Trends Immunol"},{"issue":"12","key":"10.1016\/j.vaccine.2022.01.050_b0065","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1086\/509619","article-title":"Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom","volume":"194","author":"Auckland","year":"2006","journal-title":"J Infect Dis"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2022.01.050_b0070","doi-asserted-by":"crossref","first-page":"B20","DOI":"10.1016\/j.vaccine.2009.04.067","article-title":"Meningococcal C conjugate vaccine: the experience in England and Wales","volume":"27","author":"Campbell","year":"2009","journal-title":"Vaccine"},{"issue":"9431","key":"10.1016\/j.vaccine.2022.01.050_b0075","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0140-6736(04)16725-1","article-title":"Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction","volume":"364","author":"Trotter","year":"2004","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.vaccine.2022.01.050_b0080","series-title":"Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States, 2020","author":"Centers for Disease Control and Prevention","year":"2020"},{"key":"10.1016\/j.vaccine.2022.01.050_b0085","unstructured":"World Health Organization (WHO). Table 2: Summary of WHO Position Papers \u2013 Recommended Routine Immunizations for Children. Geneva, Switzerland: World Health Organization (WHO); 2020."},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2022.01.050_b0090","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/j.jcpa.2007.04.014","article-title":"The nature and consequences of intra- and inter-vaccine interference","volume":"137","author":"Vidor","year":"2007","journal-title":"J Comp Pathol"},{"issue":"6","key":"10.1016\/j.vaccine.2022.01.050_b0095","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1080\/21645515.2020.1733869","article-title":"Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in healthy toddlers: a Phase II randomized study","volume":"16","author":"Vesikari","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2022.01.050_b0100","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1017\/S0950268821000261","volume":"149","author":"van der Vliet","year":"2021","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2022.01.050_b0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S0950268821000698","article-title":"Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) administered concomitantly with other paediatric vaccines in toddlers: a Phase III randomized study","volume":"149","author":"Dhingra","year":"2021","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2022.01.050_b0110","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1097\/INF.0000000000002832","article-title":"Safety and immunogenicity of a quadrivalent meningococcal conjugate vaccine in healthy meningococcal-na\u00efve children 2\u20139 years of age: a Phase III,randomized study","volume":"39","author":"Baccarini","year":"2020","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2022.01.050_b0115","first-page":"1","article-title":"Immunogenicity and safety of an investigational quadrivalent meningococcal conjugate vaccine administered as a booster dose in children vaccinated against meningococcal disease 3 years earlier as toddlers: a Phase III, open-label, multi-center study","author":"Piazza","year":"2021","journal-title":"Hum Vaccin Immunother"},{"issue":"19","key":"10.1016\/j.vaccine.2022.01.050_b0120","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1016\/j.vaccine.2020.03.017","article-title":"A Phase II, randomized, immunogenicity and safety study of a quadrivalent meningococcal conjugate vaccine, MenACYW-TT, in healthy adolescents in the United States","volume":"38","author":"Chang","year":"2020","journal-title":"Vaccine"},{"issue":"33","key":"10.1016\/j.vaccine.2022.01.050_b0125","doi-asserted-by":"crossref","first-page":"5194","DOI":"10.1016\/j.vaccine.2020.06.013","article-title":"Immunogenicity, safety and inter-lot consistency of a meningococcal conjugate vaccine (MenACYW-TT) in adolescents and adults: a Phase III randomized study","volume":"38","author":"Dhingra","year":"2020","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2022.01.050_b0130","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1080\/21645515.2020.1733867","article-title":"Immunogenicity and safety of a booster dose of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adolescents and adults: a Phase III randomized study","volume":"16","author":"\u00c1\u00f1ez","year":"2020","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"10.1016\/j.vaccine.2022.01.050_b0135","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1080\/21645515.2020.1733868","article-title":"Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adults 56 years of age and older: a Phase II randomized study","volume":"16","author":"Kirstein","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2022.01.050_b0140","doi-asserted-by":"crossref","first-page":"4405","DOI":"10.1016\/j.vaccine.2020.04.067","article-title":"Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in >\/=56-year-olds: a Phase III randomized study","volume":"38","author":"Esteves-Jaramillo","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.01.050_b0145","unstructured":"United States Food and Drug Administration (FDA). MenQuadfi\u2122 \u2013 Summary Basis for Regulatory Action, April 22, 2020. Rockville, MD: United States Food and Drug Administration (FDA); 2020."},{"key":"10.1016\/j.vaccine.2022.01.050_b0150","unstructured":"International Council for Harmonisation. Clinical Safety Data Management: Definitions and Standards for Expedited Reporting E2A. Geneva, Switzerland; 1994."},{"key":"10.1016\/j.vaccine.2022.01.050_b0155","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1097\/INF.0b013e318268dfe4","article-title":"Safety and immunogenicity of a quadrivalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine in infants and toddlers: three multicenter phase III studies","volume":"31","author":"Pina","year":"2012","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"10.1016\/j.vaccine.2022.01.050_b0160","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1128\/cdli.4.2.156-167.1997","article-title":"Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group","volume":"4","author":"Maslanka","year":"1997","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2022.01.050_b0165","series-title":"Training manual for enzyme linked immunosorbent assay for the quantitation of Streptococcus pneumoniae serotype specific IgG (Pn PS ELISA; 007sp Version)","author":"Goldblatt","year":"2000"},{"issue":"4","key":"10.1016\/j.vaccine.2022.01.050_b0170","first-page":"514","article-title":"Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides","volume":"10","author":"Wernette","year":"2003","journal-title":"Clin Diagn Lab Immunol"},{"issue":"8","key":"10.1016\/j.vaccine.2022.01.050_b0175","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E","article-title":"Two-sided confidence intervals for the single proportion: comparison of seven methods","volume":"17","author":"Newcombe","year":"1998","journal-title":"Stat Med"},{"key":"10.1016\/j.vaccine.2022.01.050_b0180","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.01075","article-title":"Kawasaki disease and the use of the rotavirus vaccine in children: a systematic review and meta-analysis","volume":"10","author":"Mellone","year":"2019","journal-title":"Front Pharmacol"},{"issue":"26","key":"10.1016\/j.vaccine.2022.01.050_b0185","doi-asserted-by":"crossref","first-page":"3929","DOI":"10.1016\/j.vaccine.2012.03.080","article-title":"Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine administered concomitantly with measles, mumps, rubella, varicella vaccine in healthy toddlers","volume":"30","author":"Klein","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.01.050_b0190","unstructured":"ClinicalTrials.gov. Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine when administered concomitantly with routine pediatric vaccines in healthy infants and toddlers in the US (NCT03537508); 2018."},{"key":"10.1016\/j.vaccine.2022.01.050_b0195","unstructured":"ClinicalTrials.gov. Immunogenicity and safety study of a quadrivalent meningococcal conjugate vaccine when co-administered with routine pediatric vaccines in healthy infants and toddlers in Europe (NCT03547271); 2018."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22000962?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22000962?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:09:47Z","timestamp":1759403387000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22000962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0264410X22000962"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.01.050","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and immunogenicity of an investigational quadrivalent meningococcal tetanus toxoid conjugate vaccine (MenACYW-TT) co-administered with routine pediatric vaccines in infants and toddlers: A Phase II study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.01.050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}